These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 16842460)

  • 1. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.
    Hindorf U; Lindqvist M; Hildebrand H; Fagerberg U; Almer S
    Aliment Pharmacol Ther; 2006 Jul; 24(2):331-42. PubMed ID: 16842460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
    Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG
    Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
    Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
    De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
    Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
    Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
    Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
    Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
    Shah JA; Edwards CM; Probert CS
    Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):169-73. PubMed ID: 18301295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.
    Winter J; Walker A; Shapiro D; Gaffney D; Spooner RJ; Mills PR
    Aliment Pharmacol Ther; 2004 Sep; 20(6):593-9. PubMed ID: 15352906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
    Cao Q; Zhu Q; Shang Y; Gao M; Si J
    Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
    Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
    Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
    Gilissen LP; Bierau J; Derijks LJ; Bos LP; Hooymans PM; van Gennip A; Stockbrügger RW; Engels LG
    Aliment Pharmacol Ther; 2005 Oct; 22(7):605-11. PubMed ID: 16181300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.
    Gazouli M; Pachoula I; Panayotou I; Mantzaris G; Syriopoulou VP; Goutas N; Vlachodimitropoulos D; Anagnou NP; Roma-Giannikou E
    J Clin Pharm Ther; 2010 Feb; 35(1):93-7. PubMed ID: 20175817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease.
    Hindorf U; Johansson M; Eriksson A; Kvifors E; Almer SH
    Aliment Pharmacol Ther; 2009 Mar; 29(6):654-61. PubMed ID: 19183142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
    Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
    Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
    Hindorf U; Lyrenäs E; Nilsson A; Schmiegelow K
    Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
    Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB
    Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse effects of azathioprine in the treatment of inflammatory bowel disease.
    Martínez F; Nos P; Pastor M; Garrigues V; Ponce J
    Rev Esp Enferm Dig; 2001 Dec; 93(12):769-78. PubMed ID: 11995359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.